Navigation Links
The Hepatitis C Virus Drug Market Will Nearly Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
Date:11/16/2010

BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launch of several novel agents, the hepatitis C virus (HCV) drug market will more than triple from approximately $2 billion in 2009 to nearly $7.5 billion in 2014 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will substantially decrease to $4.6 billion in 2019 due to decreasing prevalence of the disease and the high efficacy of new treatment regimens.

The Pharmacor 2010 findings from the topic entitled Hepatitis C Virus reveal that the standard of care for the indication will change significantly with the introduction of new classes of HCV-specific antiviral agents, such as protease inhibitors and polymerase inhibitors. Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care -- peg-IFN/ribavirin.

"Although complete elimination of peg-IFNs and ribavirin agents is highly desirable owing to their side effects, this change is unlikely to occur over the next decade," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "However, decreased treatment durations resulting from the addition of new antivirals could increase the tolerability of treatment regimens. The launch of novel HCV-specific agents will increase the size of the drug-treated population, owing mainly to re-treatment of prior non-responders as well as increased referral and drug-treatment rates."

The current standard of care for HCV -- often a nearly year-long treatment -- cures only about half of patients and is associated with severe side effects. Although the incidence of HCV has declined dramatically after the introduction of prevention measures such as blood donor screening in the early 1990s, prevalence is still high due to the large cohort of aging HCV-infected patients, many of whom have failed prior treatment and are waiting for new therapeutic options.

The findings also reveal that, owing to the large commercial potential which is well-recognized by drug developers, the HCV pipeline remains highly competitive. Agents in late-stage development -- namely Vertex/Johnson & Johnson/Mitsubishi Tanabe Pharma's telaprevir, Merck's boceprevir, Johnson & Johnson/Medivir's TMC-435, Roche/Pharmasset's RG-7128 and Pfizer's filibuvir -- are each expected to drive HCV market growth through 2019. Over the next several years, HCV treatment is expected to consist of cocktails of therapies that target HCV with different mechanisms of action.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
2. AASLD Presidents Choice Lecture: The National Strategy for the Control of Viral Hepatitis and Liver Cancer
3. Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants
4. Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes
5. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
6. Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test
7. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Millions of Americans Are Living With Hidden Epidemics of Hepatitis B and C, Top Experts Warn
10. Launch of Novel Agents for the Treatment of Hepatitis C Virus Will Precipitate Treatment of At Least Half of Warehoused Patients
11. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):